摘要
急性肾损伤(AKI)是临床常见的综合征,已成为世界性的公共卫生问题。肾缺血再灌注损伤(IRI)是AKI最常见的原因.。到目前为止,有效的目前仍缺乏对肾脏IRI的治疗,导致AKI的高死亡率。间充质干细胞(MSCs),被认为是组织修复和再生医学的一种很有前途的候选细胞。近年来,自我更新和多谱系分化的能力引起了越来越多的关注。以MSC为基础的治疗在肾I中的潜在作用已引起广泛关注。里。骨髓间充质干细胞具有抗炎、免疫调节的作用,能减轻肾IRI,改善肾功能。MSCs优先迁移到受伤的地点,以发挥组织修复的作用。此外,MSCs还可以通过旁分泌因子改变微环境,促进受损肾小管细胞的恢复。然而,不良的肾定向归位和缺血环境下生存能力差,限制了其有益作用。基因修饰是提高MSCs治疗作用的有效途径。骨髓间充质干细胞经外源基因修饰美国基因增强了它们的先天特性。本文就基因修饰MSCs的研究现状、生物学特性及其在肾IRI中的应用作一综述。
关键词: 间充质干细胞,基因修饰,肾缺血再灌注损伤,活性氧种类。
Current Gene Therapy
Title:Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury
Volume: 17 Issue: 6
关键词: 间充质干细胞,基因修饰,肾缺血再灌注损伤,活性氧种类。
摘要: Acute Kidney Injury (AKI) is a common syndrome in the clinic and has become a worldwide public health problem. Renal Ischemia-Reperfusion Injury (IRI) is the most common cause of AKI. So far, effective treatment is still lacking for renal IRI, resulting in a high mortality rate of AKI. Mesenchymal Stem Cells (MSCs), considered as a promising candidate for tissue repair and regenerative medicine have aroused an increasing concern in recent years for the capacity of self-renewal and multi-lineage differentiation. MSC-based therapy has drawn wide attention for its therapeutic potential in renal IRI. The administrated MSCs can alleviate the renal IRI and improve the renal function for its anti-inflammatory, immunomodulation properties. MSCs preferentially migrate into injured sites to play the role of tissue repair. Furthermore, MSCs can modify the microenvironment to promote the recovery of damaged renal tubular cells via paracrine factors. However, the poor kidney-directional homing and poor survival under ischemia environment have limited their beneficial effects. Genetic modification is an effective approach to increase the therapeutic action of MSCs. MSCs are modified with exogenous genes to enhance their innate properties. Here we review the current knowledge of gene-modified MSCs, their biological characteristics and applications in renal IRI.
Export Options
About this article
Cite this article as:
Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214094253
DOI https://dx.doi.org/10.2174/1566523218666180214094253 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Synthetic and Natural Coumarins as Antioxidants
Mini-Reviews in Medicinal Chemistry Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine
Current Vascular Pharmacology PKC Delta and Epsilon in Drug Targeting and Therapeutics
Recent Patents on DNA & Gene Sequences NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Regulation of Matrix Synthesis, Remodeling and Accumulation in Glomerulosclerosis
Current Pharmaceutical Design Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Human Mesenchymal Stem Cells Increases Expression of α-Tubulin and Angiopoietin 1 and 2 in Focal Cerebral Ischemia and Reperfusion
Current Neurovascular Research Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Melatonin and Male Reproductive Health: Relevance of Darkness and Antioxidant Properties
Current Molecular Medicine Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Cellular Mechanisms in Perinatal Hypoxic-Ischemic Brain Injury
Current Pediatric Reviews Myocardial Cellular Damage and Antioxidant Status in Off-Pump Versus On-Pump Coronary Artery Bypass Grafting - A Prospective Study
Vascular Disease Prevention (Discontinued) Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides
Current Pharmaceutical Design “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition